We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

woensdag 6 september 2017

Leukemia - Table of Contents alert Volume 31 Issue 9

If you are unable to see the message below, click here to view.

Volume 31, Issue 9 (September 2017)

In this issue
Concise Review
Original Articles
Letters to the Editor

Also new
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Follow on Twitter
Celebrating 30 years of Leukemia — 1987 to 2017

Thank you to the editors, board members, contributors, reviewers and readers, past and present for their invaluable contributions, and for bringing the journal to this milestone.

Watch our anniversary video showing a brief impact overview >>>



New drugs in myeloma: beware of phase I trial results, beware of cost and demand for new trials

P Moreau

Leukemia 2017 31: 1843-1844; advance online publication, June 30, 2017; 10.1038/leu.2017.188

Full Text



Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era

L Falchi, H M Kantarjian and S Verstovsek

Leukemia 2017 31: 1845-1854; advance online publication, May 22, 2017; 10.1038/leu.2017.150

Abstract | Full Text

Gemtuzumab ozogamicin in acute myeloid leukemia

C D Godwin, R P Gale and R B Walter

Leukemia 2017 31: 1855-1868; advance online publication, June 13, 2017; 10.1038/leu.2017.187

Abstract | Full Text

Concise Review


CHIP, ICUS, CCUS and other four-letter words

R Bejar

Leukemia 2017 31: 1869-1871; advance online publication, June 8, 2017; 10.1038/leu.2017.181

Abstract | Full Text

Original Articles



Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)

V M Patel, K Balakrishnan, M Douglas, T Tibbitts, E Y Xu, J L Kutok, M Ayers, A Sarkar, R Guerrieri, W G Wierda, S O'Brien, N Jain, H M Stern and V Gandhi

Leukemia 2017 31: 1872-1881; advance online publication, December 26, 2016; 10.1038/leu.2016.382

Abstract | Full Text

Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22

F Arruga, B Gizdic, C Bologna, S Cignetto, R Buonincontri, S Serra, T Vaisitti, K Gizzi, N Vitale, G Garaffo, E Mereu, F Diop, F Neri, D Incarnato, M Coscia, J Allan, R Piva, S Oliviero, R R Furman, D Rossi, G Gaidano and S Deaglio

Leukemia 2017 31: 1882-1893; advance online publication, December 26, 2016; 10.1038/leu.2016.383

Abstract | Full Text

Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy

G Cutrona, S Matis, M Colombo, C Massucco, G Baio, F Valdora, L Emionite, S Fabris, A G Recchia, M Gentile, C E Neumaier, D Reverberi, R Massara, S Boccardo, L Basso, S Salvi, F Rosa, M Cilli, S Zupo, M Truini, P Tassone, M Calabrese, M Negrini, A Neri, F Morabito, F Fais and M Ferrarini

Leukemia 2017 31: 1894-1904; advance online publication, January 5, 2017; 10.1038/leu.2016.394

Abstract | Full Text

PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions

Y-J Li, L Sun, Y Shi, G Wang, X Wang, S E Dunn, C Iorio, R A Screaton and D E Spaner

Leukemia 2017 31: 1905-1914; advance online publication, January 4, 2017; 10.1038/leu.2016.395

Abstract | Full Text

Trends in overall survival and costs of multiple myeloma, 2000–2014 OPEN

R Fonseca, S Abouzaid, M Bonafede, Q Cai, K Parikh, L Cosler and P Richardson

Leukemia 2017 31: 1915-1921; advance online publication, December 23, 2016; 10.1038/leu.2016.380

Abstract | Full Text

Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial

L Rosiñol, A Oriol, A I Teruel, A L de la Guía, MaJ Blanchard, J de la Rubia, M Granell, MaA Sampol, L Palomera, Y González, MaA Etxebeste, R Martínez-Martínez, M T Hernández, F de Arriba, A Alegre, MaT Cibeira, MaV Mateos, J Martínez-López, J J Lahuerta, J San Miguel and J Bladé on behalf of the Programa Español de Tratamientos en Hematología/Grupo Español de Mieloma (PETHEMA/GEM)

Leukemia 2017 31: 1922-1927; advance online publication, January 23, 2017; 10.1038/leu.2017.35

Abstract | Full Text


The clonal origins of leukemic progression of myelodysplasia

T Kim, M S Tyndel, H J Kim, J-S Ahn, S H Choi, H J Park, Y-k Kim, D-H Yang, J-J Lee, S-H Jung, S Y Kim, Y H Min, J-W Cheong, S K Sohn, J H Moon, M Choi, M Lee, Z Zhang and D(D H) Kim

Leukemia 2017 31: 1928-1935; advance online publication, January 16, 2017; 10.1038/leu.2017.17

Abstract | Full Text

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms

J Rinke, J P Müller, M F Blaess, A Chase, M Meggendorfer, V Schäfer, N Winkelmann, C Haferlach, N C P Cross, A Hochhaus and T Ernst

Leukemia 2017 31: 1936-1943; advance online publication, June 19, 2017; 10.1038/leu.2017.190

Abstract | Full Text

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes OPEN

U Platzbecker, A Symeonidis, E N Oliva, J S Goede, M Delforge, J Mayer, B Slama, S Badre, E Gasal, B Mehta and J Franklin

Leukemia 2017 31: 1944-1950; advance online publication, June 19, 2017; 10.1038/leu.2017.192

Abstract | Full Text


Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells

D T Saenz, W Fiskus, Y Qian, T Manshouri, K Rajapakshe, K Raina, K G Coleman, A P Crew, A Shen, C P Mill, B Sun, P Qiu, T M Kadia, N Pemmaraju, C DiNardo, M-S Kim, A J Nowak, C Coarfa, C M Crews, S Verstovsek and K N Bhalla

Leukemia 2017 31: 1951-1961; advance online publication, February 2, 2017; 10.1038/leu.2016.393

Abstract | Full Text


Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia

D A C Fisher, O Malkova, E K Engle, C A Miner, M C Fulbright, G K Behbehani, T B Collins, S Bandyopadhyay, A Zhou, G P Nolan and S T Oh

Leukemia 2017 31: 1962-1974; advance online publication, December 23, 2016; 10.1038/leu.2016.377

Abstract | Full Text

PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias

C Ronchini, A Brozzi, L Riva, L Luzi, A M Gruszka, G E M Melloni, E Scanziani, G Dharmalingam, M Mutarelli, V Belcastro, S Lavorgna, V Rossi, O Spinelli, A Biondi, A Rambaldi, F Lo-Coco, D di Bernardo and P G Pelicci

Leukemia 2017 31: 1975-1986; advance online publication, December 27, 2016; 10.1038/leu.2016.386

Abstract | Full Text

Letters to the Editor


Spotlight on pomalidomide: could less be more? OPEN

T Zander, S Aebi, T Pabst, C Renner and C Driessen

Leukemia 2017 31: 1987-1989; advance online publication, May 22, 2017; 10.1038/leu.2017.156

Full Text

Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia

A M Heilmann, A B Schrock, J He, M Nahas, K Curran, N Shukla, S Cramer, L Draper, A Verma, R Erlich, J Ross, P Stephens, V A Miller, S M Ali, J-A Verglio, M S Tallman and T I Mughal

Leukemia 2017 31: 1989-1992; advance online publication, May 29, 2017; 10.1038/leu.2017.161

Full Text

Identification of a novel PML-RARG fusion in acute promyelocytic leukemia

J-S Ha, Y R Do, C-S Ki, C Lee, D-H Kim, W Lee, N-H Ryoo and D-S Jeon

Leukemia 2017 31: 1992-1995; advance online publication, May 30, 2017; 10.1038/leu.2017.167

Full Text

MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations

A Stengel, W Kern, M Meggendorfer, T Haferlach and C Haferlach

Leukemia 2017 31: 1995-1997; advance online publication, June 8, 2017; 10.1038/leu.2017.180

Full Text

Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004–2014

A D'Souza, M-J Zhang, J Huang, M Fei, M Pasquini, M Hamadani and P Hari

Leukemia 2017 31: 1998-2000; advance online publication, June 13, 2017; 10.1038/leu.2017.185

Full Text

The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia OPEN

A Rio-Machin, G Gómez-López, J Muñoz, F Garcia-Martinez, A Maiques-Diaz, S Alvarez, R N Salgado, M Shrestha, R Torres-Ruiz, C Haferlach, M J Larráyoz, M J Calasanz, J Fitzgibbon and J C Cigudosa

Leukemia 2017 31: 2000-2005; advance online publication, June 20, 2017; 10.1038/leu.2017.194

Full Text

Recurrent cyclin D2 mutations in myeloid neoplasms

V Khanna, C A Eide, C E Tognon, J E Maxson, B Wilmot, D Bottomly, S McWeeney, D K Edwards V, B J Druker and J W Tyner

Leukemia 2017 31: 2005-2008; advance online publication, June 20, 2017; 10.1038/leu.2017.195

Full Text



Do we need to distinguish exosomes from microvesicles in hematological malignancies?

A Caivano, L Del Vecchio and P Musto

Leukemia 2017 31: 2009-2010; advance online publication, June 28, 2017; 10.1038/leu.2017.205

Full Text

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature